Ketamine Decreases Resting State Functional Network Connectivity in Healthy Subjects: Implications for Antidepressant Drug Action

• Published in: PloS one Vol. 7; no. 9; p. e44799
• Main Authors: Scheidegger, Milan, Walter, Martin, Lehmann, Mick, Metzger, Coraline, Grimm, Simone, Boeker, Heinz, Boesiger, Peter, Henning, Anke, Seifritz, Erich
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 24.09.2012; Public Library of Science (PLoS)
• Subjects: Adult; Affective disorders; Antidepressants; Antidepressive Agents - pharmacology; Biology; Biomedical engineering; Brain; Brain Mapping; Brain research; Clinical trials; Cognitive ability; Cortex (cingulate); Cortex (temporal); Cross-Over Studies; Data processing; Depression (Mood disorder); Depressive Disorder, Major - drug therapy; Depressive Disorder, Major - pathology; Dosage and administration; Double-Blind Method; Drug therapy; Emotional disorders; Engineering; Female; Functional magnetic resonance imaging; Functional plasticity; Glutamatergic transmission; Glutamic acid receptors (ionotropic); Gyrus Cinguli - anatomy & histology; Gyrus Cinguli - drug effects; Gyrus Cinguli - physiology; Humans; Information processing; Injections, Intravenous; Intervention; Intravenous administration; Ketamine; Ketamine - pharmacology; Laboratories; Magnetic resonance; Magnetic Resonance Imaging; Male; Medical imaging; Medicine; Mental depression; Middle Aged; N-Methyl-D-aspartic acid receptors; Neural networks; Neural Pathways - anatomy & histology; Neural Pathways - drug effects; Neural Pathways - physiology; Neurobiology; Neuroimaging; Neurophysiology; Neurosciences; NMR; Nuclear magnetic resonance; Physiology; Placebos; Prefrontal cortex; Prefrontal Cortex - anatomy & histology; Prefrontal Cortex - drug effects; Prefrontal Cortex - physiology; Psychiatry; Septal Nuclei - anatomy & histology; Septal Nuclei - drug effects; Septal Nuclei - physiology; Signaling; Studies; Temporal lobe; Switzerland; Germany
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0044799

Increasing preclinical and clinical evidence underscores the strong and rapid antidepressant properties of the glutamate-modulating NMDA receptor antagonist ketamine. Targeting the glutamatergic system might thus provide a novel molecular strategy for antidepressant treatment. Since glutamate is the...